The purpose of this study is to compare changes in HIV levels and certain immune cells among
patients at different stages of HIV infection. This study will also see how a combination of
stavudine (d4T), lamivudine (3TC), indinavir (IDV), and nelfinavir (NFV) affects these
Current findings in anti-HIV drug treatment have led to a greater understanding of the
background of HIV. To find the best anti-HIV treatment to eliminate all HIV viruses, cells
and tissues infected with the HIV virus are examined after combination anti-HIV treatment,
when the level of HIV infection is low. The ERADICATE study will examine the idea that HIV
viruses can be eliminated at any stage of infection over time.
Recent advancements in antiretroviral therapy have led to a better understanding of the
natural history and immunopathogenesis of HIV-1 infection. To calculate the degree and
duration of antiretroviral effect necessary to eliminate infection, characterization of
residual cellular and tissue HIV reservoirs following high-level viral suppression is
necessary. The ERADICATE study will evaluate the hypothesis that complete viral inhibition
is possible, regardless of HIV disease stage, and leads to HIV eradication from tissues over
Patients are divided into 1 of 5 groups based on the stage of HIV infection. Patients
receive oral stavudine (d4T), lamivudine (3TC), indinavir (IDV), and nelfinavir (NFV) twice
daily for 24 weeks. All patients undergo basic blood sampling to follow HIV-1 RNA levels and
absolute T cell subset numbers daily for 5 days; then 3 times a week for 3 weeks; 2 times a
week for 4 weeks; every 2 weeks for 12 weeks; and monthly thereafter for a total of 3 years.
In addition, the following tissues are sampled at baseline and after 2 weeks and 6 months on
therapy: 1) lymph node; 2) tonsillar; 3) perirectal lymphoid; 4) cerebrospinal fluid; 5) and
Patients may be eligible for this study if they:
- Are infected with HIV and have had certain tests to indicate the stage of their
- Are at least 18 years old.
- Practice birth control during the study.
Patients will not be eligible for this study if they:
- Have received anti-HIV medication for more than 1 week.
- Have a serious AIDS-related infection or other illness.
- Require medication that interferes with the study drugs.
- Have had a peripheral neuropathy, a painful condition affecting the nervous system.
- Have been given drugs that affect the immune system within 2 weeks before study
- Have a bleeding disorder including hemophilia.
- Abuse alcohol or substances.
- Are pregnant or breast-feeding.